Published in Life Sci on March 01, 1978
Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J (1978) 3.90
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) (1982) 2.39
The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol (1979) 2.29
Evidence of different metabolic phenotypes in humans. Proc Natl Acad Sci U S A (2008) 2.06
LC-MS-based metabolomics in drug metabolism. Drug Metab Rev (2007) 1.79
Genetically determined oxidation capacity and the disposition of debrisoquine. Br J Clin Pharmacol (1983) 1.19
Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet (1984) 1.11
Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. Proc Natl Acad Sci U S A (1984) 0.84
Debrisoquine oxidation phenotype and susceptibility to lung cancer. Br J Clin Pharmacol (1990) 0.77
The development of molecular epidemiology to elucidate cancer risk and prognosis: a historical perspective. Int J Mol Epidemiol Genet (2010) 0.75
Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics. Drug Saf Case Rep (2017) 0.75
Chicken liver ribosomes: characterization of cross-reaction and inhibition of some functions by antibodies prepared against Escherichia coli ribosomal proteins L7 and L12. J Mol Biol (1976) 12.86
Polymorphic hydroxylation of Debrisoquine in man. Lancet (1977) 9.36
Changes in physicians' attitudes toward telling the cancer patient. JAMA (1979) 7.75
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet (1980) 5.68
Biliary excretion of foreign compounds. Biphenyl, stilboestrol and phenolphthalein in the rat: molecular weight, polarity and metabolism as factors in biliary excretion. Biochem J (1967) 5.33
More on SI units. N Engl J Med (1992) 4.34
Biliary excretion of foreign compounds. Benzene and its derivatives in the rat. Biochem J (1967) 3.97
Lowry determination of protein in the presence of Triton X-100. Anal Biochem (1975) 3.94
Polymorphism of carbon oxidation of drugs and clinical implications. Br Med J (1978) 3.90
Effect of organic contamination upon microbial distributions and heterotrophic uptake in a Cape Cod, Mass., aquifer. Appl Environ Microbiol (1984) 3.06
Denitrification in san francisco bay intertidal sediments. Appl Environ Microbiol (1984) 3.03
Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry (1997) 2.71
Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (1993) 2.60
Phosphate-regulated inactivation of the kinase PHO80-PHO85 by the CDK inhibitor PHO81. Science (1994) 2.57
Biliary excretion in foreign compounds. Sulphonamide drugs in the rat. Biochem J (1967) 2.53
Biliary excretion in foreign compounds. Species difference in biliary excretion. Biochem J (1967) 2.52
Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) (1982) 2.39
The metabolism of [14C]-debrisoquine in man. Br J Clin Pharmacol (1979) 2.29
Measured context-sensitive half-times of remifentanil and alfentanil. Anesthesiology (1995) 2.26
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (1984) 2.17
Body malodour syndromes. Lancet (1995) 2.12
Nitrogen Fixation in Grasses Inoculated with Spirillum lipoferum. Science (1976) 2.09
Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica (1979) 2.07
Science, medicine, and the future: Pharmacogenetics. BMJ (2000) 2.06
False positives with current carbocisteine protocol for sulphoxidation phenotyping. Lancet (1990) 2.05
Trimethylaminuria: the fish malodor syndrome. Drug Metab Dispos (2001) 1.96
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. J Med Genet (1983) 1.92
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
Reovirus infection and tissue injury in the mouse central nervous system are associated with apoptosis. J Virol (1997) 1.90
Dietary precursors of trimethylamine in man: a pilot study. Food Chem Toxicol (1999) 1.90
The St. Mary's Hospital sleep questionnaire: a study of reliability. Sleep (1981) 1.86
Quantitation of glycosaminoglycan hexosamine using 3-methyl-2-benzothiazolone hydrazone hydrochloride. Anal Biochem (1979) 1.85
Poor metabolisers of debrisoquine reveal their true colours. Lancet (1989) 1.84
Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. Nat Genet (1997) 1.83
The metabolic fate of amphetamine in man and other species. Biochem J (1970) 1.80
A fibronectin receptor on Candida albicans mediates adherence of the fungus to extracellular matrix. J Infect Dis (1991) 1.78
The exogenous origin of trimethylamine in the mouse. Metabolism (1992) 1.78
The biliary excretion of tartrazine. Sex differences in the rat and species differences in the rat, guinea-pig and rabbit. J Pharm Pharmacol (1972) 1.77
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev (1979) 1.71
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Nerve growth factor-dependence of herpes simplex virus latency in peripheral sympathetic and sensory neurons in vitro. J Neurosci (1990) 1.69
Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet (1999) 1.68
Comparison of low- and high-passage bovine turbinate cells for assay of bovine viral diarrhea virus. Arch Gesamte Virusforsch (1974) 1.65
Use of molecular techniques to evaluate the survival of a microorganism injected into an aquifer. Appl Environ Microbiol (1994) 1.64
The fate of benzoic acid in various species. Biochem J (1970) 1.62
The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol Chemother (1965) 1.62
The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci (1992) 1.61
Short-term adaptation in single auditory nerve fibers: some poststimulatory effects. J Neurophysiol (1977) 1.59
Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules. Diabetes Care (1999) 1.58
Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J (1972) 1.57
The fish odour syndrome: biochemical, familial, and clinical aspects. BMJ (1993) 1.57
The influence of dietary methylxanthines on the metabolism and pharmacokinetics of intravenously administered theophylline [proceedings]. Br J Clin Pharmacol (1977) 1.55
Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur J Cancer (1996) 1.54
Rapid and short-term adaptation in auditory nerve responses. Hear Res (1984) 1.52
The fate of amphetamine in man and other mammals. J Pharm Pharmacol (1966) 1.51
Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis (1997) 1.49
Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J Natl Cancer Inst (1992) 1.49
Signaling pathways for tumor necrosis factor-alpha and interleukin-6 expression in human macrophages exposed to titanium-alloy particulate debris in vitro. J Bone Joint Surg Am (1999) 1.49
Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease. Mov Disord (2000) 1.48
Inhibition of existing denitrification enzyme activity by chloramphenicol. Appl Environ Microbiol (1992) 1.47
Physician knowledge in the use of canister nebulizers. Chest (1983) 1.47
The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol Chemother (1965) 1.46
Lung cancer risk in African-Americans in relation to a race-specific CYP1A1 polymorphism. Cancer Res (1995) 1.46
CYP2D6 multiallelism. Methods Enzymol (1996) 1.45
Alteration of the Fe protein of nitrogenase by oxygen in the cyanobacterium Anabaena sp. strain CA. J Bacteriol (1987) 1.44
The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol (1992) 1.44
A genetic polymorphism of the N-oxidation of trimethylamine in humans. Clin Pharmacol Ther (1987) 1.44
The metabolism of 14C-labelled trimethylamine and its N-oxide in man. Xenobiotica (1987) 1.44
Prediction of glycosaminoglycan content in human cartilage by age, T1ρ and T2 MRI. Osteoarthritis Cartilage (2010) 1.43
Dynamic structure of membranes by deuterium NMR. Science (1984) 1.43
CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst (1997) 1.43
Prophylactic antibiotics in clean orthopaedic surgery. J Bone Joint Surg Am (1974) 1.43
Glucosaminidase, galactosaminidase, and glucuronidase in the growth plate. J Orthop Res (1990) 1.42
Embryotoxic activity of some pesticides and drugs related to phthalimide. Food Cosmet Toxicol (1965) 1.40
Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics (1995) 1.39
The long and the short of drug safety. Lancet (1993) 1.39
Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet (1993) 1.39
Bile and urine as complementary pathways for the excretion of foreign organic compounds. Xenobiotica (1976) 1.38
Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet (1992) 1.38
Adaptation, saturation, and physiological masking in single auditory-nerve fibers. J Acoust Soc Am (1979) 1.36
Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest (1993) 1.36